Predictive role of skin rash in advanced pancreatic cancer patients treated with gemcitabine plus erlotinib: a systematic review and meta-analysis

References

• SiegelRLMillerKDJemalACancer Statistics, 2017Ca-Cancer J Clin 20172017671730
   PubMed Web of Science ®Google Scholar
• Bond-SmithGBangaNHammondTMImberCJPancreatic adenocarcinomaBMJ201234416e247622592847
   PubMed Web of Science ®Google Scholar
• RegistryHKCHong Kong Cancer Statistics2015 Available from: http://www3.ha.org.hk/cancereg/pdf/overview/Summary%20of%20CanStat%202015.pdfAccessedJanuary 17, 2018
   Google Scholar
• WilkowskiRWolfMHeinemannVPrimary advanced unresectable pancreatic cancerRecent Results Cancer Res2008177799318084950
   PubMedGoogle Scholar
• ChanSLChanSTChanEHHeZXZxHSystemic treatment for inoperable pancreatic adenocarcinoma: review and updateChin J Cancer201433626727624472302
   PubMedGoogle Scholar
• BurrisHA3rdMooreMJAndersenJImprovements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trialJ Clin Onco199715624032413
   PubMed Web of Science ®Google Scholar
• MooreMJGoldsteinDHammJErlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials GroupJ Clin Oncol200725151960196617452677
   PubMed Web of Science ®Google Scholar
• von HoffDDErvinTArenaFPIncreased survival in pancreatic cancer with nab-paclitaxel plus gemcitabineN Engl J Med2013369181691170324131140
   PubMed Web of Science ®Google Scholar
• ConroyTDesseigneFYchouMFOLFIRINOX versus gemcitabine for metastatic pancreatic cancerN Engl J Med2011364191817182521561347
   PubMed Web of Science ®Google Scholar
• ArandaEManzanoJLRiveraFPhase II open-label study of erlotinib in combination with gemcitabine in unresectable and/or metastatic adenocarcinoma of the pancreas: relationship between skin rash and survival (Pantar study)Ann Oncol20122371919192522156621
   PubMed Web of Science ®Google Scholar
• BeveridgeRDAlcoleaVAparicioJManagement of advanced pancreatic cancer with gemcitabine plus erlotinib: efficacy and safety results in clinical practiceJOP2014151192424413779
   PubMedGoogle Scholar
• PetrelliFBorgonovoKCabidduMLonatiVBarniSRelationship between skin rash and outcome in non-small-cell lung cancer patients treated with anti-EGFR tyrosine kinase inhibitors: a literature-based meta-analysis of 24 trialsLung Cancer201278181522795701
   PubMed Web of Science ®Google Scholar
• SoulieresDSenzerNNVokesEEHidalgoMAgarwalaSSSiuLLMulticenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neckJ Clin Oncol2004221778514701768
   PubMed Web of Science ®Google Scholar
• KlapdorRKlapdorSBahloMCombination therapy with gemcitabine (GEM) and erlotinib (E) in exocrine pancreatic cancer under special reference to RASH and the tumour marker CA19-9Anticancer Res20123252191219722593509
   PubMed Web of Science ®Google Scholar
• RenoufDJTangPAHedleyDA phase II study of erlotinib in gemcitabine refractory advanced pancreatic cancerEur J Cancer201450111909191524857345
   PubMed Web of Science ®Google Scholar
• FeliuJBorregaPLeónAPhase II study of a fixed dose-rate infusion of gemcitabine associated with erlotinib in advanced pancreatic cancerCancer Chemother Pharmacol201167121522120927525
   PubMed Web of Science ®Google Scholar
• Munoz LlarenaALopez-VivancoGRuiz de LoberaAGem-citabine (G) fixed-dose-rate infusion (FDR) plus erlotinib (E) in patients with advanced pancreatic cancer (APC)J Clin Onco2011294_suppl304
   Web of Science ®Google Scholar
• ParkSChungMJParkJYPhase II trial of erlotinib plus gemcitabine chemotherapy in korean patients with advanced pancreatic cancer and prognostic factors for chemotherapeutic responseGut Liver20137561161524073321
   PubMed Web of Science ®Google Scholar
• OhDYLeeKWLeeKHA phase II trial of erlotinib in combination with gemcitabine and capecitabine in previously untreated metastatic/recurrent pancreatic cancer: combined analysis with translational researchInvest New Drugs20123031164117421404106
   PubMed Web of Science ®Google Scholar
• MuñozAAzkonaEIzaEIEfficacy and safety of fixed-dose-rate infusions of gemcitabine plus erlotinib for advanced pancreatic cancerJ Anal Oncol2015414451
   Google Scholar
• ParmarMKTorriVStewartLExtracting summary statistics to perform meta-analyses of the published literature for survival endpointsStat Med19981724281528349921604
   PubMed Web of Science ®Google Scholar
• WellsGSheaBO’ConnellDThe Newcastle–Ottawa Scale (NOS) for Assessing the Quality of Non-Randomized Studies in Meta-Analysis Available from: http://www.medicine.mcgill.ca/rtamblyn/Readings%5CThe%20Newcastle%20-%20Scale%20for%20assessing%20the%20quality%20of%20nonrandomised%20studies%20in%20meta-analyses.pdfAccessed January 17, 2018
   Google Scholar
• ZangJXiangCHeJSynthesis of median survival time in meta-analysisEpidemiology201324233733823377098
   PubMed Web of Science ®Google Scholar
• HigginsJPThompsonSGDeeksJJAltmanDGMeasuring inconsistency in meta-analysesBMJ2003327741455756012958120
   PubMed Web of Science ®Google Scholar
• GSe HJPT [homepage on the Internet]Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. The Cochrane Collaboration2011 Available from: www.handbook.cochrane.orgAccessed January 17, 2018
   Google Scholar
• TangJLLiuJLJlyLMisleading funnel plot for detection of bias in meta-analysisJ Clin Epidemiol200053547748410812319
   PubMed Web of Science ®Google Scholar
• DuvalSTweedieRTrim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysisBiometrics200056245546310877304
   PubMed Web of Science ®Google Scholar
• WackerBNagraniTWeinbergJWittKClarkGCagnoniPJCorrelation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studiesClin Cancer Res200713133913392117606725
   PubMed Web of Science ®Google Scholar
• OkusakaTFuruseJFunakoshiAPhase II study of erlotinib plus gemcitabine in Japanese patients with unresectable pancreatic cancerCancer Sci2011102242543121175992
   PubMed Web of Science ®Google Scholar
• StepanskiEJReyesCWalkerMSThe association of rash severity with overall survival: findings from patients receiving erlotinib for pancreatic cancer in the community settingPancreas2013421323622699203
   PubMed Web of Science ®Google Scholar
• van CutsemEVervenneWLBennounaJPhase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancerJ Clin Oncol200927132231223719307500
   PubMed Web of Science ®Google Scholar
• VaccaroVBriaESperdutiIFirst-line erlotinib and fixed dose-rate gemcitabine for advanced pancreatic cancerWorld J Gastroenterol201319284511451923901226
   PubMed Web of Science ®Google Scholar
• OettleHTessenHGroschekMNon-interventional study with Erlotinib/Gemcitabine in patients with metastatic pancreatic cancerOnkologie Conference201336Supplement 7123
   Google Scholar
• WangJPWuCYYehYCErlotinib is effective in pancreatic cancer with epidermal growth factor receptor mutations: a randomized, open-label, prospective trialOncotarget2015620181621817326046796
   PubMed Web of Science ®Google Scholar
• IrigoyenAGallegoJGuillén PonceCGemcitabine-erlotinib versus gemcitabine-erlotinib-capecitabine in the first-line treatment of patients with metastatic pancreatic cancer: Efficacy and safety results of a phase IIb randomised study from the Spanish TTD Collaborative GroupEur J Cancer201775738228222309
   PubMed Web of Science ®Google Scholar
• IrieKUenoMKobayashiSThe biomarkers of gemcitabine and erlotinib treatment in advanced pancreatic cancerJ Clin Oncol2014323_suppl35824366938
   PubMed Web of Science ®Google Scholar
• ChengYJBaiCMZhangZJEfficacy of Gemcitabine Combined with Erlotinib in Patients with Advanced Pancreatic CancerActaCTA Academiae Medicinae Sinica2010324421423
   Google Scholar
• GuYHShuYQHuangPWObservation of Erlotinib (Tarceva) combined with gemcitabine in advanced pancreatic adenocarcinomaChin Clin Oncol2006117515517
   Google Scholar
• GuoXDXuWSunCHClinical effect of Erlotinib plus gemcitabine in treatment of advanced pancreas cancerChin J of Clinical Rational Drug Use201252B2122
   Google Scholar
• LiuHBWuYLvTFSkin rash could predict the response to EGFR tyrosine kinase inhibitor and the prognosis for patients with non-small cell lung cancer: a systematic review and meta-analysisPLoS One201381e5512823383079
   PubMed Web of Science ®Google Scholar
• PetrelliFBorgonovoKBarniSThe predictive role of skin rash with cetuximab and panitumumab in colorectal cancer patients: a systematic review and meta-analysis of published trialsTarget Oncol20138317318123321777
   PubMed Web of Science ®Google Scholar
• MaoCYangZYHuXFChenQTangJLPIK3CA exon 20 mutations as a potential biomarker for resistance to anti-EGFR monoclonal antibodies in KRAS wild-type metastatic colorectal cancer: a systematic review and meta-analysisAnn Oncol20122361518152522039088
   PubMed Web of Science ®Google Scholar
• FjällskogMLLejonklouMHObergKEErikssonBKJansonETExpression of molecular targets for tyrosine kinase receptor antagonists in malignant endocrine pancreatic tumorsClin Cancer Res2003941469147312684421
   PubMed Web of Science ®Google Scholar
• LacoutureMEMechanisms of cutaneous toxicities to EGFR inhibitorsNat Rev Cancer200661080381216990857
   PubMed Web of Science ®Google Scholar
• JostMKariCRodeckUThe EGF receptor – an essential regulator of multiple epidermal functionsEur J Dermatol200010750551011056418
   PubMed Web of Science ®Google Scholar
• FallerBABurtnessBTreatment of pancreatic cancer with epidermal growth factor receptor-targeted therapyBiologics2009341942819774209
   PubMedGoogle Scholar
• van CutsemELiCPNowaraEDose escalation to rash for erlotinib plus gemcitabine for metastatic pancreatic cancer: the phase II RACHEL studyBr J Cancer2014111112067207525247318
   PubMed Web of Science ®Google Scholar
• HidalgoMSiuLLNemunaitisJPhase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignanciesJ Clin Oncol200119133267327911432895
   PubMed Web of Science ®Google Scholar
• GoodinSErlotinib: optimizing therapy with predictors of response?Clin Cancer Res200612102961296316707589
   PubMed Web of Science ®Google Scholar
• EisenhauerEATherassePBogaertsJNew response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)Eur J Cancer200945222824719097774
   PubMed Web of Science ®Google Scholar
• DhaniNTuDSargentDJSeymourLMooreMJAlternate endpoints for screening phase II studiesClin Cancer Res20091561873188219276273
   PubMed Web of Science ®Google Scholar
• LynchTJKimESEabyBGareyJWestDPLacoutureMEEpidermal growth factor receptor inhibitor-associated cutaneous toxicities: an evolving paradigm in clinical managementOncologist200712561062117522250
   PubMed Web of Science ®Google Scholar